

# European Paediatric Formulation Initiative (EuPFI)

**EuPFI Newsletter**  
 ISSUE OF MONTH NOVIO

Newsletter Nov10  
 Volume 1, Issue 1

## Inside this issue:

2 <sup>nd</sup> Annual Conference Recap	1
3 <sup>rd</sup> Annual conference announcement	2
EuPFI membership	2
Workgroups updates	3

## 2<sup>nd</sup> Annual Conference Recap

‘Formulating Better medicines for Children’ 2010

The EuPFI second annual conference was held on 21<sup>st</sup> and 22<sup>nd</sup> September 2010 in Berlin, Germany. It was organized in partnership with APV.

A packed programme, including presentations on topics such as challenges and issues associated age-appropriateness of dosage forms, excipients, taste masking and taste assessment, administration devices, extemporaneous formulations, and new developments for the global market were enjoyed by over 180 delegates from 25 countries comprising representatives from pharmaceutical industry (large and small), academia, several European regulatory

agencies (including MHRA (UK), EMA, FIMEA (Finland), Swissmedic, NoMA (Norway) AEMPS (Spain), and exhibitors (Losan Pharma, Rottendorf Pharma etc.) exhibited throughout the conference.

It aimed at exchanging experiences and lessons learnt so far. In addition to the programme of presentations, there was a large poster display outside of the main auditorium. This provided an excellent backdrop for networking during the refreshment breaks.

The EuPFI were pleased to welcome Dr Wang [EMA], Dr Williams [Pfizer], Dr Giacoia [NIH & USPFI] and Dr Hill [WHO], as the key note speakers for this conference (shown below).



“Well Done!!  
 Very successful and beneficial conference. I like the way all the aspects of paediatric development was discussed.”



## Conference Highlights:

- It was focused on highlighting the challenges/barriers that impede progress of paediatric drug development, and explored bridges to overcome such barriers.
- The conference offered significant opportunity to share experiences & expertise in developing paediatric formulations from a global perspective.





The plenary talks were targeted to give an insight into the regulatory and industrial considerations of paediatric formulations, and US and Developing World perspectives. It was focused on highlighting the challenges/barriers that impede progress, and explored bridges to overcome such barriers. A fast-paced 'soap box' session followed with thematic focus session covered the main challenges related to the clinical administration of paediatric

formulations. For example: acceptability of tablets and capsules depending on the size and the age, palatability of oral formulations, industry verified preparations and extemporaneous dispensing, recent developments in delivery devices and safety of excipients in the paediatric population. Consistent with the aims of EuPFI, the conference offered significant opportunity to share experiences & expertise in developing paediatric formulations from a global

perspective. The meeting also provided an additional framework for academic, industry and the regulators to debate the issues.

The proceedings/abstracts and oral presentations of the conference are published on our website [www.eupfi.org](http://www.eupfi.org)



## EuPFI 3<sup>rd</sup> Annual Conference 1<sup>st</sup> Announcement



### IMPORTANT DATES FOR YOUR DIARY:

Call for Abstracts - Open 15<sup>th</sup> Jan 2010

Abstract Submission - Deadline 5<sup>th</sup> May 2010

Notification of Acceptance - 1<sup>st</sup> June 2010

Conference Early Bird Registration due - 1<sup>st</sup> July 2010

We have started the initial preparation for the 3<sup>rd</sup> Conference on formulating better medicines for children and we are considering several alternatives to enhance our technical program. You will all receive further announcements in the near future and we hope we can count again with your support. Thank you very much for all your support and your efforts to

make EuPFI 2010 a very successful conference and we hope to see you all at the EuPFI 2011 conference. Please keep in mind the possibility of organizing special sessions, and feel free to contact EuPFI ([info@eupfi.org](mailto:info@eupfi.org)) with any comments and suggestions about possible improvements to the conference.

## EuPFI Core members

### Accademia

Royal Liverpool Children's NHS Trust & MCRN  
The School of Pharmacy, University of London  
University of Ghent  
University of Dusseldorf

### Industry

Astra Zeneca  
Boehringer Ingelheim  
Pharma GmbH  
GlaxoSmithKline  
Merck Sharp & Dohme  
Novartis  
Roche  
Sanofi Aventis

### Organisations

Association of Commercial Specials Manufacturers  
International Pharmaceutical Excipients Council Europe  
EMA (observer)

For membership applications please see our website for different levels of membership and if interested please contact us.

## EuPFI Work Groups Update

### Administration Devices

Purpose of workgroup:

This group is considering the challenges in availability of and development of delivery devices for consistent administration of paediatric formulations.

The group is preparing a paper for publication 'Challenges and Recent Developments in Delivery Devices for the Administration of Paediatric Formulations.

### Extemporaneous Dispensing

This group is considering challenges associated with use of extemporaneous preparations for paediatric patients

The group has prepared a reflection paper on 'Extemporaneous Dispensing and Industry-verified Preparation' ready for submission for publication. The groups is also working on number of other papers covering topics including the use of extemporaneous preparation in Europe, Transition of industry verified preparation to commercials etc,

### Pharmaceutical Excipients

This group is developing a database compiling safety and toxicity information of excipients likely to be used in paediatrics (dSTEPs).

The group has developed a methodology to collect the information from published literature and has explored the database systems and developers.

### Taste Masking and Taste Testing

This group is considering taste masking technologies and platforms and identifying methodologies for taste assessment.

The group is preparing a paper for publication on taste making technologies.

### Age Appropriateness of Formulations

This is a newly formed group that will consider age appropriate formulations.

European Paediatric  
Formulation Initiative  
The School of Pharmacy,  
University of London,  
29-39 Brunswick square  
London WC1N 1AX

E-mail address:  
[info@eupfi.org](mailto:info@eupfi.org)

Web site address:  
[www.eupfi.org](http://www.eupfi.org)

**Formulating Better  
Medicines for children**



This Newsletter covers  
highlights for anyone  
interested in EuPFI  
activities.